House bill · H.R. 10227 (119th Congress)
INSULIN Act of 2026
U.S. House of Representatives
Sponsor: Diana DeGette (U.S. Representative, CO-1, Democratic)
Following needs an Agora account. You will sign in first, then come back to this page.
From Congress.gov and official rosters. This record was last updated Sep 7, 2026. About our data
Summary
This bill would cap cost-sharing for selected insulin products at $35 per 30-day supply, limiting patient out-of-pocket costs for multiple types of insulin with waived deductibles.
AI summary. Not an official summary. How we handle summaries
Where it stands
Assigned to a committee for review.
- Introduced
- In committee
- Up for a vote
- Passed one chamber
- Passed
- Enacted
Committee
House Committee on Energy and Commerce · U.S. House of Representatives
Your position on this bill
Choose the position closest to yours. You'll sign in or create an account to save it.
Cosponsors
Showing the cosponsors who are on Agora, A to Z. The official record may list more.
Read on Congress.gov (opens in a new tab)- Democratic1
Shown in neutral colors by design; Agora is non-partisan.
Full history
- Sep 2, 2026
Introduced
Introduced in House
U.S. House of Representatives
- Sep 2, 2026
Introduced
Introduced in U.S. House
U.S. House
- Sep 2, 2026
Referred to committee
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Sep 2, 2026
Referred to committee
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Read the record
- Read on Congress.gov (opens in a new tab) The official record on Congress.gov.